biotech / news / / MarketScreener
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis.
Gilead Sciences will acquire Tubulis for up to $5 billion, including $3.15 billion upfront.
KEY POINTS
- Tubulis' lead asset, TUB-040, is in Phase 1b/2 trials for ovarian and lung cancer.
- The acquisition includes TUB-030, an ADC with promising early data in various solid tumors.
- Gilead will fund the Tubulis deal with cash on hand and senior unsecured notes.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →